Quarterly report pursuant to Section 13 or 15(d)

Note 11 - Segment Information (Tables)

v3.6.0.2
Note 11 - Segment Information (Tables)
 6 Months Ended
Dec. 31, 2016
Notes Tables  
Schedule of Segment Reporting Information, by Segment [Table Text Block]
 
 
Quarter Ended
 
 
Six Months Ended
 
 
 
December 31,
 
 
December 31,
 
 
 
2016
 
 
2015
 
 
2016
 
 
2015
 
Net sales:
                                
Biotechnology
   $
85,953
     $
75,854
     $
172,740
     $
151,597
  
Diagnostics
    
24,330
      
25,723
      
48,563
      
46,085
  
Protein Platforms
    
21,548
      
19,337
      
41,121
      
35,634
  
Intersegment
    
(24
)
    
(7
)
    
(36
)
    
(28
)
Consolidated net sales
   $
131,807
     $
120,907
     $
262,388
     $
233,288
  
Segment operating income:
                                
Biotechnology
   $
39,474
     $
39,986
     $
81,954
     $
79,302
  
Diagnostics
    
5,801
      
7,297
      
12,104
      
12,010
  
Protein Platforms
    
1,843
      
1,528
      
2,052
      
356
  
Subtotal reportable segments
    
47,118
      
48,811
      
96,110
      
91,668
  
Costs recognized on sale of acquired inventory
    
(3,848
)
    
(1,245
)
    
(8,069
)
    
(2,357
)
Amortization of acquisition related intangible assets
    
(11,627
)
    
(7,361
)
    
(21,815
)
    
(14,772
)
Acquisition related expenses
    
(10,732
)
    
(670
)
    
(15,101
)
    
(970
)
Stock based compensation
    
(4,055
)
    
(2,321
)
    
(7,245
)
    
(4,359
)
Corporate general, selling, and administrative
    
(710
)
    
(1,189
)
    
(2,293
)
    
(2,156
)
Consolidated operating income
   $
16,146
     $
36,025
     $
41,587
     $
67,054